5-aminocarbonyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine

ADCI, also known as SGB-017, is a glutamate receptor antagonist potentially for the treatment of epilepsy. ADCI blocks both voltage-activated sodium channels and N-methyl-D-aspartate (NMDA)-receptor-gated channels. Inhibition of sodium channels by ADCI was voltage dependent. High doses of ADCI increased dopamine metabolism in the prefrontal cortex and/or in the nucleus accumbens, but not in the dorsal striatum.

ADCI, a noncompetitive NMDA antagonist, is a broad-spectrum anticonvulsant agent[1].

[1] M A Rogawski, et al. Anticonvulsant efficacy of ADCI (5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine) after acute and chronic dosing in mice. Epilepsia. 1995 Jun;36(6):566-71. DOI:10.1111/j.1528-1157.1995.tb02568.x